<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="30813">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02705573</url>
  </required_header>
  <id_info>
    <org_study_id>2021/2014</org_study_id>
    <nct_id>NCT02705573</nct_id>
  </id_info>
  <brief_title>Effects of Mannitol on Delayed Graft Function After Cadaveric Renal Transplantation</brief_title>
  <official_title>Effects of Mannitol on Delayed Graft Function After Cadaveric Renal Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <brief_summary>
    <textblock>
      In this project we want to evaluate the effect of mannitol on graft function after renal
      transplantation. Due to the unclear situation regarding data of Mannitoleffect and lack of
      standardization during the kidney transplant, there is an indication for performing a
      randomized trial.

      We are planning to perform a double-blind randomized controlled trial . In the study,
      mannitol 20% with a dose of 1g / kg / KG will be compared to placebo with NaCl 0.9% in the
      dose of 5 ml / kg / KG. Patients will be randomized to receive either the mannitol or NaCl.
      The follow-up of the study is a week. Data will be collected, compared and published at the
      end of the study. It is planned to include a total of 100 patients in the study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>eGFR</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Kidney Transplantation, Mannitol</condition>
  <arm_group>
    <arm_group_label>Mannitol 20%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mannitol 1g/KG BW</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nacl 0.9%</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>NaCl 0.9% 5ml/KG BW</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mannitol</intervention_name>
    <arm_group_label>Mannitol 20%</arm_group_label>
    <arm_group_label>Nacl 0.9%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: all patient with end stage renal diseases -

        Exclusion Criteria: alergy to mannitol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Samir Sljivic, Dr.</last_name>
    <phone>+4314040041020</phone>
    <email>samir.sljivic@meduniwien.ac.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samir Sljivic, Dr</last_name>
      <phone>004314040041020</phone>
      <email>samir.sljivic@meduniwien.ac.at</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <lastchanged_date>March 7, 2016</lastchanged_date>
  <firstreceived_date>March 7, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Samir Sljivic</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Delayed Graft Function</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mannitol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
